Date:3/9/2010

>

The application of U.S. GAAP would result in material differences in the Company's accounting policies related to patent costs, technology licenses acquired from third-parties and stock-based compensation. Cardiome does not expect the adoption of U.S. GAAP to require significant changes to the Company's existing internal controls over financial reporting and disclosure controls and procedures, or information and data systems.

Conference Call

Cardiome will hold a teleconference and webcast on Tuesday, March 9, 2010 at 4:30pm Eastern (1:30pm Pacific). To access the conference call, please dial 416-340-2217 or 866-696-5910 and reference conference 1276021. There will be a separate dial-in line for analysts on which we will respond to questions at the end of the call. The webcast can be accessed through Cardiome's website at www.cardiome.com.

'/>"/>

SOURCE Cardiome Pharma Corp. Copyright©2010 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans
2. Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
3. Cardiome to Release Third Quarter Results
4. Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial
5. Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
6. Cardiome Pharma Corp. Announces Final Results of Tender Offer
7. Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer
8. Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009
9. Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares
10. Atherotech Adds New Cardiometabolic Tests Amid Strong 2009 Growth
11. Cardiome to Hold Conference Call